Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 9/20 | 0.55 |
| ▸ | BLM | P54132 | 7/20 | 0.55 |
| ▸ | LMNA | P02545 | 5/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.55 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.52 |
| ▸ | RECQL | P46063 | 7/20 | 0.52 |
| ▸ | MAPT | P10636 | 6/20 | 0.52 |
| ▸ | APEX1 | P27695 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.52 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.52 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43825 | 0.81 | BLM (0.62) | TDP1BLMLMNAADRA1ANR1I2 | |
| SCHEMBL29881886 | 0.81 | BLM (0.62) | TDP1BLMLMNAADRA1ANR1I2 | |
| SCHEMBL28135952 | 0.81 | BLM (0.62) | TDP1BLMLMNAADRA1ANR1I2 | |
| SCHEMBL29935536 | 0.81 | BLM (0.62) | TDP1BLMLMNAADRA1ANR1I2 | |
| SCHEMBL43826 | 0.81 | BLM (0.62) | TDP1BLMLMNAADRA1ANR1I2 | |
| SCHEMBL10085813 | 0.81 | BLM (0.62) | TDP1BLMLMNAADRA1ANR1I2 | |
| SCHEMBL12189556 | 0.79 | TDP1 (0.50) | TDP1BLMLMNAADRA1ANR1I2 | |
| SCHEMBL10786647 | 0.79 | BLM (0.61) | TDP1BLMLMNAADRA1ANR1I2 | |
| SCHEMBL10721569 | 0.79 | TDP1 (0.55) | TDP1BLMLMNAADRA1ANR1I2 | |
| SCHEMBL9313443 | 0.79 | TDP1 (0.52) | TDP1BLMLMNAADRA1ANR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759435-B2 | Dihydrochalcone derivatives influencing inflammatory states | SYMRISE AG (DE) | 2023-09-19 | — | — | US | disclosed |
| US-20220226261-A1 | DIHYDROCHALCONE DERIVATIVES INFLUENCING INFLAMMATORY STATES | SYMRISE AG (DE) | 2022-07-21 | — | — | US | disclosed |
| CN-109310649-B | Dihydrochalcone derivatives affecting inflammatory states | 西姆莱斯有限公司 | 2021-06-29 | — | — | CN | disclosed |
| US-10758468-B2 | Solubilizer for cosmetic preparations | SYMRISE AG (DE) | 2020-09-01 | — | — | US | disclosed |
| EP-2633886-B1 | COMPOUNDS AND MIXTURES INFLUENCING INFLAMMATORY STATES | SYMRISE AG (DE) | 2018-01-31 | — | — | EP | disclosed |
| WO-2017186298-A1 | DIHYDROCHALCONE DERIVATIVES INFLUENCING INFLAMMATORY STATES | SYMRISE AG (DE) | 2017-11-02 | — | — | WO | disclosed |
| US-20160106650-A1 | SOLUBILIZER FOR COSMETIC PREPARATIONS | SYMRISE AG (DE) | 2016-04-21 | — | — | US | disclosed |
| EP-2455157-B1 | SOLUBILIZER FOR COSMETIC PREPARATIONS | SYMRISE AG (DE) | 2016-03-23 | — | — | EP | disclosed |
| US-8961943-B2 | O/W-emulsifiers, O/W-emulsions and methods of manufacture thereof | SYMRISE AG (DE) | 2015-02-24 | — | — | US | disclosed |
| US-8906958-B2 | Compounds and mixtures for influencing inflammatory states | SYMRISE AG (DE) | 2014-12-09 | — | — | US | disclosed |
| US-20030072725-A1 | Topical cosmetic agents containing 2-hydrazino-1,3 -heteroazoles | HAARMANN & REIMER GMBH (DE) | 2003-04-17 | — | — | US | disclosed |
| US-20030069307-A1 | 2-(3,4-Dihydroxyphenyl)ethyl-substituted carbonic acid derivatives and their use | HAARMANN & REIMER GMBH (DE) | 2003-04-10 | — | — | US | disclosed |
| EP-1296937-A1 | 3,4-DIHYDROXYMANDELIC ACID ALKYLAMIDES AND USE THEREOF | HAARMANN & REIMER GMBH (DE) | 2003-04-02 | — | — | EP | disclosed |
| US-20030049287-A1 | Catechol oximes and their use in cosmetic and dermatological preparations | HAARMANN & REIMER GMBH (DE) | 2003-03-13 | — | — | US | disclosed |
| EP-1284145-A1 | 2-(3,4-Dihydroxyphenyl)ethyl substituted carbonic acid derivatives and their use | HAARMANN & REIMER GMBH (DE) | 2003-02-19 | — | — | EP | disclosed |
| EP-1239825-A1 | CATECHOL OXIMES AND THEIR USE IN COSMETIC AND DERMATOLOGICAL PREPARATIONS | HAARMANN & REIMER GMBH (DE) | 2002-09-18 | — | — | EP | disclosed |
| US-20020128268-A1 | Use of 2-hydrazino-1,3-thiazoles as antioxidants | HAARMANN & REIMER GMBH (DE) | 2002-09-12 | — | — | US | disclosed |
| WO-2002034265-A1 | USE OF 2-HYDRAZINO-1,3-THIAZOLES AS ANTIOXIDANTS | HAARMANN & REIMER GMBH (DE) | 2002-05-02 | — | — | WO | disclosed |
| WO-2001098258-A1 | 3,4-DIHYDROXYMANDELIC ACID ALKYLAMIDES AND USE THEREOF | HAARMANN & REIMER GMBH (DE) | 2001-12-27 | — | — | WO | disclosed |
| WO-2001043712-A1 | CATECHOL OXIMES AND THEIR USE IN COSMETIC AND DERMATOLOGICAL PREPARATIONS | HAARMANN & REIMER GMBH (DE) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128268-A1 | Use of 2-hydrazino-1,3-thiazoles as antioxidants | GPX1, LPO, GPX4 | TDP1 1809/4885BLM 4425/4885LMNA 2539/4885 |
| US-10758468-B2 | Solubilizer for cosmetic preparations | SRPK3, SRPK1, SYMPK | TDP1 2561/4885BLM 2047/4885LMNA 1696/4885 |
| US-20030069307-A1 | 2-(3,4-Dihydroxyphenyl)ethyl-substituted carbonic acid derivatives and their use | NFE2L2, AGER, ME2 | TDP1 549/4885BLM 4300/4885LMNA 1269/4885 |
| US-20030049287-A1 | Catechol oximes and their use in cosmetic and dermatological preparations | TYR, LPO, COMT | TDP1 989/4885BLM 3145/4885LMNA 4505/4885 |
| US-11759435-B2 | Dihydrochalcone derivatives influencing inflammatory states | IL17A, TNF, IL1B | TDP1 3846/4885BLM 2988/4885LMNA 2103/4885 |
| US-20030072725-A1 | Topical cosmetic agents containing 2-hydrazino-1,3 -heteroazoles | TYR, MITF, HDAC1 | TDP1 508/4885BLM 3725/4885LMNA 4633/4885 |
| US-20160106650-A1 | SOLUBILIZER FOR COSMETIC PREPARATIONS | SRPK3, SRPK1, SYMPK | TDP1 2561/4885BLM 2047/4885LMNA 1696/4885 |
| US-20220226261-A1 | DIHYDROCHALCONE DERIVATIVES INFLUENCING INFLAMMATORY STATES | IL17A, TNF, IL1B | TDP1 3846/4885BLM 2988/4885LMNA 2103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.